Table 1: Notable Influenza Pandemics
Table 2: Influenza Symptoms
Table 3: Risk Factors and Comorbidities for Seasonal Influenza
Table 4: 7MM, Historical Perspective of Seasonal Influenza Vaccination Coverage
Table 5: 7MM, Sources of Epidemiological Data Used to Forecast Total Population Vaccination Rates of Seasonal Influenza
Table 6: 7MM, Sources of Epidemiological Data Used to Forecast Diagnosed Incident Cases of Outpatient Seasonal ILI
Table 7: 7MM, Sources of Epidemiological Data Used to Forecast Laboratory Confirmed Incident Cases of Seasonal Influenza
Table 8: 7MM, Sources of Epidemiological Data Used to Forecast Seasonal Influenza-Related Hospitalized Incident Cases
Table 9: 7MM, Sources of Epidemiological Data Used to Forecast Averted Cases of Seasonal Influenza
Table 10: 7MM, Sources Not Used in Epidemiological Analysis of Seasonal Influenza
Table 11: 7MM, People Receiving Seasonal Influenza Vaccination, All Ages, Both Sexes, N, Selected Years 2015–2025
Table 12: 7MM, Age-Specific Distribution of People Receiving Seasonal Influenza Vaccination, Both Sexes, N (Row %), 2015
Table 13: 7MM, Sex-Specific Distribution of People Receiving Seasonal Influenza Vaccination, All Ages, N (Row %), 2015
Table 14: 7MM, Seasonal Influenza Vaccination Rates, All Ages, Both Sexes, %, Selected Years 2015–2025
Table 15: 7MM, Age-Specific Seasonal Influenza Vaccination Rates, Both Sexes, (%), 2015
Table 16: 7MM, Diagnosed Outpatient ILI Incident Cases, All Ages, Both Sexes, N, Selected Years 2015–2025
Table 17: 7MM, Age-Specific Diagnosed Outpatient ILI Incident Cases, Both Sexes, N (Row %), 2015
Table 18: 7MM, Sex-Specific Diagnosed Outpatient ILI Incident Cases, All Ages, N (Row %), 2015
Table 19: 7MM, Lab Confirmed Incident Cases of Seasonal Influenza, All Ages, Both Sexes, N, Selected Years 2015–2025
Table 20: 7MM, Age-Specific Lab Confirmed Incident Cases of Seasonal Influenza, Both Sexes, N (Row %), 2015
Table 21: 7MM, Lab Confirmed Incident Cases of Seasonal Influenza, All Ages, N (Row %), 2015
Table 22: 7MM, Influenza-Related Hospitalized Incident Cases, All Ages, Both Sexes, N, Selected Years 2015–2025
Table 23: 7MM, Age-Specific Influenza-Related Hospitalized Incident Cases, Both Sexes, N (Row %), 2015
Table 24: 7MM, Influenza Related Hospitalized Incident Cases, All Ages, N (Row %), 2015
Table 25: 7MM, Cases Averted by Seasonal Influenza Vaccinations, All Ages, Both Sexes, N, Selected Years 2015–2025
Table 26: 7MM, Age-Specific Cases Averted by Seasonal Influenza Vaccinations, Both Sexes, N (Row %), 2015
Table 27: Seasonal Influenza Immunization Recommendation Agencies by Country, 2016
Table 28: Immunization Recommendations and Most Frequently Administered Seasonal Influenza Vaccines, 2016
Table 29: Country Profile – US
Table 30: Country Profile – France
Table 31: Country Profile – Germany
Table 32: Country Profile – Italy
Table 33: Country Profile – Spain
Table 34: Country Profile – UK
Table 35: Country Profile –Japan
Table 36: Leading Seasonal Influenza Vaccines, 2016
Table 37: Product Profile – Fluzone Quadrivalent
Table 38: Immunogenicity Profile of Fluzone Quadrivalent
Table 39: Local and Systemic AEs of Fluzone Quadrivalent
Table 40: Fluzone Quadrivalent SWOT Analysis, 2016
Table 41: Global Sales Forecast ($m) for Fluzone Quadrivalent, 2015–2025
Table 42: Product Profile – Fluzone High-Dose
Table 43: Immunogenicity of Fluzone High-Dose Compared with Fluzone
Table 44: Local and Systemic AEs of Fluzone High-Dose
Table 45: Fluzone High-Dose SWOT Analysis, 2016
Table 46: Global Sales Forecast ($m) for Fluzone High-Dose, 2015–2025
Table 47: Product Profile – Fluzone Intradermal
Table 48: Comparison of Fluzone Intradermal Quadrivalent Versus Fluzone Intradermal Trivalent
Table 49: Local andsystemic AEs of Fluzone Intradermal Quadrivalent
Table 50: Fluzone Intradermal Quadrivalent SWOT Analysis, 2016
Table 51: Global Sales Forecast ($m) for Fluzone/Intanza Intradermal, 2015–2025
Table 52: Product Profile – Vaxigrip
Table 53: Cumulative Incidence of Influenza Infection in Children
Table 54: Local and Systemic AEs of Vaxigrip
Table 55: Vaxigrip SWOT Analysis, 2016
Table 56: Global Sales Forecast ($m) for Vaxigrip, 2015–2025
Table 57: Product Profile – Fluarix Tetra
Table 58: Immunogenicity Profile of Fluarix Tetra
Table 59: Local and Systemic AEs of Fluarix Tetra
Table 60: Fluarix Tetra SWOT Analysis, 2016
Table 61: Global Sales Forecast ($m) for Fluarix Tetra, 2015–2025
Table 62: Product Profile – Fluvirin
Table 63: Immunogenicity of Fluvirin in Adults
Table 64: Local and Systemic AEs of Fluvirin
Table 65: Fluvirin SWOT Analysis, 2016
Table 66: Global Sales Forecast ($m) for Fluvirin, 2015–2025
Table 67: Product Profile – Afluria
Table 68: Immunogenicity of Afluria in Adults
Table 69: Local and Systemic AEs of Afluria
Table 70: Afluria SWOT Analysis, 2016
Table 71: Global Sales Forecast ($m) for Afluria, 2015–2025
Table 72: Product Profile – Agrippal
Table 73: Immunogenicity of Agrippal
Table 74: Local and Systemic AEs of Agrippal
Table 75: Agrippal SWOT Analysis, 2016
Table 76: Global Sales Forecast ($m) for Agrippal, 2015–2025
Table 77: Product Profile – Fluad
Table 78: Immunogenicity Comparison of Fluad Versus Agriflu
Table 79: Local and Systemic AEs of Fluad
Table 80: Fluad SWOT Analysis, 2016
Table 81: Global Sales Forecast ($m) for Fluad, 2015–2025
Table 82: Product Profile – FluMist Quadrivalent
Table 83: Noninferiority of FluMist Quadrivalent Compared with FluMist Trivalent
Table 84: AEs of FluMist Quadrivalent
Table 85: FluMist Quadrivalent SWOT Analysis, 2016
Table 86: Global Sales Forecast ($m) for FluMist Quadrivalent, 2015–2025
Table 87: Product Profile – Flublok
Table 88: Immunogenicity of Flublok compared with Fluzone and Fluzone High-Dose
Table 89: Local and Systemic AEs of Flublok
Table 90: Flublok SWOT Analysis, 2016
Table 91: Global Sales Forecast ($m) for Flublok, 2015–2025
Table 92: Product Profile – Flucelvax
Table 93: Immunogenicity of Flucelvax
Table 94: Local and Systemic AEs of Flucelvax
Table 95:Flucelvax SWOT Analysis, 2016
Table 96: Global Sales Forecast ($m) for Flucelvax, 2015–2025
Table 97: Summary of Other Marketed Seasonal Influenza Vaccines, 2016
Table 98: Unmet Need and Opportunity in Seasonal Influenza Vaccines, 2016
Table 99: Seasonal Influenza Vaccines – Late-Stage Pipeline, 2016
Table 100: Quadrivalent Versions of Marketed Vaccines
Table 101: Product Profile – Seasonal Influenza VLP Vaccine
Table 102: Seasonal Influenza VLP Vaccine SWOT Analysis, 2016
Table 103: Global Sales Forecast ($m) for Seasonal Influenza VLP Vaccine, 2015–2025
Table 104: Product Profile – VN-100
Table 105: Comparison of Immunogenicity Profile of VN-100 and Subcutaneous Standard Vaccine
Table 106: Frequency of Local and Systemic AEs of VN-100 Compared with a Comparator Subcutaneous Vaccine
Table 107: VN-100 SWOT Analysis, 2016
Table 108: Global Sales Forecast ($m) for VN-100, 2015–2025
Table 109: Product Profile – Quadrivalent Seasonal Influenza VLP Vaccine
Table 110: Quadrivalent Seasonal Influenza VLP Vaccine SWOT Analysis, 2016
Table 111: Global Sales Forecast ($m) for Quadrivalent Seasonal Influenza VLP Vaccine, 2015–2025
Table 112: Promising Vaccines in Early-Stage Development, 2016
Table 113: Summary of Seasonal Influenza Vaccines in Development Outside the 7MM, 2016
Table 114: Key Companies in the Seasonal Influenza Vaccines Market, 2016
Table 115: Sanofi’s Seasonal Influenza Vaccine Portfolio Assessment, 2016
Table 116: CSL Limited’s Seasonal Influenza Vaccine Portfolio Assessment, 2016
Table 117: GSK’s Seasonal Influenza Vaccine Portfolio Assessment, 2016
Table 118: AstraZeneca’s Seasonal Influenza Vaccine Portfolio Assessment, 2016
Table 119: Protein Sciences Corporation’s Seasonal Influenza Vaccine Portfolio Assessment, 2016
Table 120: Mitsubishi’s Seasonal Influenza Vaccine Portfolio Assessment, 2016
Table 121: Novavax’s Seasonal Influenza Vaccine Portfolio Assessment, 2016
Table 122: Global (7MM) Sales Forecasts ($m) for Seasonal Influenza Vaccines, 2015–2025
Table 123: Seasonal Influenza Vaccines Market – Drivers and Barriers, 7MM, 2015–2025
Table 124: Sales Forecasts ($m) for Seasonal Influenza Vaccines in the US, 2015–2025
Table 125: Key Events Impacting Sales for Seasonal Influenza in the US, 2015?2025
Table 126: US Seasonal Influenza Vaccines Market – Drivers and Barriers, 2015?2025
Table 127: Sales Forecasts ($m) for Seasonal Influenza Vaccines in France, 2015 –2025
Table 128: Key Events Impacting Sales for Seasonal Influenza in France, 2015?2025
Table 129: France Seasonal Influenza Vaccines Market – Drivers and Barriers, 2015?2025
Table 130: Sales Forecasts ($m) for Seasonal Influenza Vaccines in Germany, 2015 –2025
Table 131: Key Events Impacting Sales for Seasonal Influenza in Germany, 2015?2025
Table 132: Germany Seasonal Influenza Vaccines Market – Drivers and Barriers, 2015?2025
Table 133: Sales Forecasts ($m) for Seasonal Influenza Vaccines in Italy, 2015–2025
Table 134: Key Events Impacting Sales for Seasonal Influenza in Italy, 2015?2025
Table 135: Italy Seasonal Influenza Vaccines Market – Drivers and Barriers, 2015?2025
Table 136: Sales Forecasts ($m) for Seasonal Influenza Vaccines in Spain, 2015 –2025
Table 137: Key Events Impacting Sales for Seasonal Influenza in Spain, 2015?2025
Table 138: Spain Seasonal Influenza Vaccines Market – Drivers and Barriers, 2015?2025
Table 139: Sales Forecasts ($m) for Seasonal Influenza Vaccines in the UK, 2015–2025
Table 140: Key Events Impacting Sales for Seasonal Influenza in the UK, 2015?2025
Table 141: UK Seasonal Influenza Vaccines Market – Drivers and Barriers, 2015?2025
Table 142: Sales Forecasts ($m) for Seasonal Influenza Vaccines in Japan, 2015–2025
Table 143: Key Events Impacting Sales for Seasonal Influenza in Japan 2015?2025
Table 144: Japan Seasonal Influenza Vaccines Market – Drivers and Barriers, 2015?2025
Table 145: Key Launch Dates
Table 146: High-Prescribing Physicians (non-KOLs) Surveyed, By Country